AZD3965 is an investigational drug that acts as a potent and selective inhibitor of monocarboxylate transporter 1 (MCT1). By targeting this transporter, which is often overexpressed in various tumor types… Read more
AZD3965 is an investigational drug that acts as a potent and selective inhibitor of monocarboxylate transporter 1 (MCT1). By targeting this transporter, which is often overexpressed in various tumor types to facilitate lactate export and metabolic adaptation, the compound plays a crucial role in disrupting cancer cell metabolism. The availability of high-quality reference standards, metabolites, and stable isotope-labelled compounds for this category is essential for researchers engaged in rigorous impurity profiling and method validation. Pharmaceutical laboratories utilize these materials to ensure accurate quantification and characterization during both preclinical and clinical drug development. By providing precise analytical tools for detecting degradants and monitoring metabolic pathways, these reference materials support the comprehensive quality control and safety assessments required for investigating MCT1 inhibition as a therapeutic strategy in oncology research.